Diastereomeric peptides for modulating t cell immunity
AssigneeYeda Research and Developent Co., Ltd. at the Weizman Institute of Science
InventorsYechiel Shai, Irun R. Cohen, Francisco Quintana, Doron Gerber
Life of this patent
Estimating the term…
Abstract
The present invention provides diastereomeric peptides derived from the T Cell Receptor alpha Transmembrane Domain, and lipophilic conjugates thereof, which peptides and conjugates are effective in preventing or treating T cell mediated inflammatory diseases. The invention provides pharmaceutical compositions comprising these diastereomeric peptides and conjugates, and uses thereof for therapy of inflammatory diseases, autoimmunity and graft rejection.
Claims38
1-54. (canceled)
A diastereomeric peptide derived from a T cell receptor (TCR) alpha chain transmembrane domain, the peptide comprising at least two basic amino acid residues.
A peptide derived from a T cell receptor (TCR) alpha chain transmembrane domain, the peptide comprising at least two basic amino acid residues, wherein all amino acid residues of said peptide are of the “D” isomer configuration.
Dependencies are inferred from the claim text.